CT P24

Drug Profile

CT P24

Latest Information Update: 17 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celltrion
  • Developer Celltrion; Valneva; Yonsei University Health System
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Hepatitis B

Most Recent Events

  • 16 Mar 2016 Early research development is ongoing in South Korea (Celltrion pipeline, March 2016)
  • 31 Dec 2011 Early research in Hepatitis B (Treatment-resistant) in South Korea (unspecified route) before December 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top